Limited Benefit of Adjuvant Chemotherapy in Older Women With HR-Positive, HER2-Negative Breast Cancer
The ASTER 70s trial found that adjuvant chemotherapy provided no significant survival benefit, but caused substantial toxicity in older women…
Electronic Benefit Verification with Surescripts – Life Sciences Today Podcast Episode 23
We’re excited to be back for another episode of the Life Sciences Today Podcast by Healthcare IT Today. I am…
Logistics management is leveling up with generative AI
Large shippers and TMS vendors have started to incorporate the emerging technology over the last few years with an eye on cutting…
Dulaglutide Biosimilar Achieves Equivalent Efficacy in HbA1c Reduction in Patients With T2DM
A new biosimilar, LY05008, shows comparable efficacy and safety to dulaglutide in managing type 2 diabetes mellitus (T2DM) in Chinese…
Ransomware attack on DaVita exposes data from 2.7M
The data breach is one of the largest healthcare incidents reported to federal regulators this year.
Perspective From UGM: What Epic’s Launch of AI-Native Scribing Means for Health Systems and the Startups that Serve Them
The following is a guest article by Yair Saperstein, MD MPH, CEO and Co-Founder of Avo As many anticipated, Epic…
7-Eleven taps former Amazon, Target exec to run demand chain
Joshua Dolan is responsible for expanding and optimizing 7-Eleven’s enterprise-wide logistics capabilities and improving execution.
Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments – 09/30/2025
On September 30, 2025 FDA will hold its annual public meeting and opportunity for public comment on Financial Transparency and…
Financial Transparency and Efficiency of the Prescription Drug User Fee Act, Biosimilar User Fee Act, and Generic Drug User Fee Amendments | 2021 – 06/28/2021
This public meeting is intended to meet performance commitments included in PDUFA VI, BsUFA II, and GDUFA II.